Kura Oncology Shares New Findings for Development of Tipifarnib

Biotech Investing

Kura Oncology released new research findings on the development of their lead candidate tipifarnib, treating bone marrow cancers.

Kura Oncology (NASDAQ:KURA) released new research findings on the development of their lead candidate tipifarnib, treating bone marrow cancers.
As quoted in the press release:

Among the findings presented at ASH were the identification of CXCR4/CXCR2 expression ratio and bone marrow homing of myeloid cells as potential biomarkers of tipifarnib activity across the bone marrow cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML), further showing that the CXCL12/CXCR4 pathway is a potential therapeutic target of farnesyl transferase inhibitors.
“Although tipifarnib has previously demonstrated clinical responses in certain patients with AML and MDS, no molecular mechanism of action was identified that could explain the activity of the drug candidate in those patient populations,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “These new findings are exciting because they may define potential biomarkers for tipifarnib in bone marrow tumors and characterize a subgroup of patients that are most likely to derive clinical benefit from a targeted therapy such as tipifarnib.”
Previously, Kura Oncology reported preliminary results from an ongoing Phase 2 clinical trial of tipifarnib in patients with peripheral T-cell lymphoma (PTCL) identifying the CXCL12/CXCR4 pathway as a potential target of tipifarnib. Specifically, high levels of CXCL12 gene expression and absence of single nucleotide gene variations in the 3′-untranslated region of the CXCL12 gene were associated with observed clinical activity of tipifarnib in these PTCL patients.

Click here to read the full press release.

Source: globenewswire.com

The Conversation (0)
×